FBIO Stock Overview
A biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Fortress Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.74 |
| 52 Week High | US$4.43 |
| 52 Week Low | US$1.36 |
| Beta | 1.68 |
| 1 Month Change | 8.07% |
| 3 Month Change | 25.18% |
| 1 Year Change | -36.73% |
| 3 Year Change | -95.40% |
| 5 Year Change | -95.27% |
| Change since IPO | -98.95% |
Recent News & Updates
Recent updates
Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry
Oct 29
Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%
Jul 26There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise
Dec 29There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding
Aug 18Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients
Aug 11David Jin is the new finance chief of Fortress Biotech
Jul 22Shareholder Returns
| FBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.9% | -3.3% | -2.2% |
| 1Y | -36.7% | -1.9% | 23.9% |
Return vs Industry: FBIO underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: FBIO underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| FBIO volatility | |
|---|---|
| FBIO Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: FBIO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: FBIO's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 186 | Lindsay Rosenwald | www.fortressbiotech.com |
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea.
Fortress Biotech, Inc. Fundamentals Summary
| FBIO fundamental statistics | |
|---|---|
| Market cap | US$47.48m |
| Earnings (TTM) | -US$57.52m |
| Revenue (TTM) | US$81.50m |
0.6x
P/S Ratio-0.8x
P/E RatioIs FBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FBIO income statement (TTM) | |
|---|---|
| Revenue | US$81.50m |
| Cost of Revenue | US$85.67m |
| Gross Profit | -US$4.17m |
| Other Expenses | US$53.35m |
| Earnings | -US$57.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.08 |
| Gross Margin | -5.12% |
| Net Profit Margin | -70.58% |
| Debt/Equity Ratio | -421.8% |
How did FBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 02:23 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fortress Biotech, Inc. is covered by 17 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Stephen V. Byrne | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |